Search hospitals

>

Wisconsin

>

Madison

University of Wisconsin

Claim this profile

Madison, Wisconsin 53792

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Lung Cancer

Conducts research for Prostate Cancer

Conducts research for Solid Tumors

952 reported clinical trials

127 medical researchers

Photo of University of Wisconsin in Madison

Summary

University of Wisconsin is a medical facility located in Madison, Wisconsin. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Solid Tumors and other specialties. University of Wisconsin is involved with conducting 952 clinical trials across 1,757 conditions. There are 127 research doctors associated with this hospital, such as Kenneth B. De Santes, Nataliya V. Uboha, Kari B. Wisinski, and Dustin Deming, M.D..

Area of expertise

1

Breast Cancer

Global Leader

University of Wisconsin has run 80 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Cancer

Global Leader

University of Wisconsin has run 77 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
MDM2 positive

Top PIs

Clinical Trials running at University of Wisconsin

Breast Cancer

Multiple Myeloma

Prostate Cancer

Brain Tumor

Smoking Cessation

Cystic Fibrosis

Stroke

Atrial Fibrillation

Idiopathic Pulmonary Fibrosis

Lung Cancer

Image of trial facility.

Gadolinium-Based Contrast Media Effects on Motor and Cognitive Functioning

for

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years. The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.

Recruiting

3 awards

Phase 4

9 criteria

Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Wisconsin?

Where is University of Wisconsin located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Wisconsin accept?

What awards or recognition has University of Wisconsin received?